Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer

Leo W. Jenkins Cancer Center

Status: Completed

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Study type: Observational

Funder types: Other

Identifiers

NCT02271581

INSYNC

Details and patient eligibility

About

There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer. Elevated c-reactive protein levels have been shown to be associated with reduced performance status, specific cancer related symptoms and reduced overall survival. C-reactive protein levels are a surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer recurrence. VeriStrat® is a multivariate test which measures protein expression related to a host/tumor interaction mediated by inflammation. The investigators hope to examine the relationship between quality of life outcomes per FACT-L survey and correlate them with changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study is that the remarkable survival benefit in the Temel study is mediated by reduced inflammation with improvement of symptom control.

Enrollment: 38 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of stage IV non-small cell lung cancer
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Able to read and respond to questions in English

Exclusion criteria

• Small Cell Lung Cancer